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INTRODUCTION 
Ellipticine (5,11-dimethyl-6H-pyrido 
[4,3-b] carbazole, figure 1) and its more 
soluble derivates are alkaloids isolated 
from Apocyanaceae plants, which exhibit 
significant antitumor activities[15, 21, 24, 31].  
Ellipticine was first isolated in 1959 from 
the leaves of the evergreen tree Ochrosia 
elliptica Labil[6]. Nevertheless, its pharmacological efficiencies (and efficiencies 
of some of its derivates) was found in 1967, when they were prepared  
by chemical syntheses[7]. Ellipticine and its more soluble derivates, 9-methoxy-
ellipticine and 2-methyl-9-hydroxyellipticine in the form of acetate, have been 
utilized pharmacologically since 1970s. They are highly efficient against 
osteolytic breast cancer with metastases, acute myeloblastic leukemia, kidney 
sarcoma and thyroid carcinoma[1, 17, 18, 19, 23]. Ellipticines exhibit also significant 
anti-HIV activity because of their ability to inhibit retroviral integrase. This is 
the reason, why ellipticine is also investigated to be used for AIDS  
treatment[24, 32].  
In organisms, cytochromes P450 oxidize ellipticine up to five metabolites, 
9-hydroxyellipticine (M1), 12-hydroxyellipticine (M2), 13-hydroxyellipticine 
(M3), 7-hydroxyellipticine (M4) and N2-oxide of ellipticine (M5). These 
metabolites are formed not only by cytochromes P450 of human liver 
microsomes, but also by those of microsomes of model organisms (rats and 
rabbits)[34]. The other enzymes catalyzing the ellipticine oxidation and its 
activation to more efficient metabolites forming DNA adducts are peroxidases. 
Two ellipticine metabolites are generated by peroxidases; the major product is 
the ellipticine dimer, in which the two ellipticine skeletons are connected via 
Figure 1 The structure of ellipticine 
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N(6) of the pyrrole ring of one ellipticine molecule and C9 in the second one. 
The minor metabolite is ellipticine N2-oxide[27, 29, 30, 37].  
The mode of action of ellipticine is considered to be based mainly on DNA 
intercalation[2, 4, 8, 19] and inhibition of topoisomerase II activity[3, 11, 13, 16, 25]. 
Ellipticine also cause selective inhibition of p53 protein phosphorylation[26, 41] 
and oxidative phosphorylation, which leads to the decrease in amounts of ATP 
in cell and its final damage[33]. It is evident that the explanations of anticancer 
activity mentioned above are based mainly on nonspecific mechanisms. 
However, this sharply contrasts with specificity of ellipticines against only 
several cancer diseases. 
A new mechanism for the ellipticine action was described, showing the 
formation of covalent DNA adducts by ellipticine, after its enzymatic activation 
with cytochromes P450 and peroxidases. These enzymes generate the 
pharmacologically more efficient derivates of ellipticine that form these DNA 
adducts. Deoxyguanosine was determined to be the target deoxynucleoside  
in DNA, to which the ellipticine reactive metabolites are bound[38].  
13-hydroxyellipticine and 12-hydroxyellipticine (the latter formed also 
spontaneously from ellipticine N2 oxide by the Polonowski rearrangement[34, 38]), 
are responsible for the formation of two major DNA adducts in vitro. 
 The formation of this CYP-mediated covalent DNA adduct by ellipticine 
was also detected in V-79 Chinese hamster lung fibroblasts transfected with 
human CYP enzymes[12], in human breast adenocarcinoma MCF-7 cells[5],  
in human leukemia cells (HL-60 and CCRF-CEM)[30] and in neuroblastoma[28] 
and glioblastoma[22] cells. Covalent DNA adducts are also generated  
by ellipticine  in vivo in some organs (livers, spleen, lungs, kidney, heart, brain) 
of rats exposed to this anticancer drug[36] and in DNA of rat breast 
adenocarcinoma[39].  
The most effective enzymes activating ellipticine to form DNA adducts 
are human and rat cytochromes P450 of the 3A and 1A subfamilies[20, 34, 38, 40]. 
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AIM OF THE STUDY 
The aim of this study was to extend our knowledge on metabolism  
of anticancer drug ellipticine and its mechanism of action. 
 
 
The aims of the present work are as follows: 
.  
 
• To study ellipticine metabolism by cytochromes P450 of a 1A subfamily 
 
• To evaluate ellipticine potential to induce the expression of cytochromes 
P450 1A1/2 in liver, lung and kidney of rats  
 
• To prepare cytochrome b5 without its hem cofactor (apo-cytochrome b5) 
 
• To investigate the effect of cytochrome b5 on ellipticine metabolism  
by CYP1A1/2 
 
• To investigate the effect of apo-cytochrome b5 and other proteins with and 
without heme in its molecule on oxidation of ellipticine by CYP1A1/2 
 
• To examine the effect of cytochrome b5, its apo-form and other proteins, 
on ellipticine oxidation by CYP3A4 
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RESULTS AND DISCUSSION 
The results shown in this study extend our knowledge on pharmacological 
effects of anticancer drug ellipticine and its mechanism of action. The main 
results found in this work are summarized as follows: 
 
The different molar ratio of NADPH:CYP reductase and CYP1A and the 
concentration of CYP1A in the reconstituted system correlate with its 
efficiency to oxidize ellipticine 
 We investigated the influence of individual compounds of the mixed 
function oxidase system on ellipticine oxidation catalyzed by CYPs of a 1A 
subfamily in vitro. The results show that efficiencies of CYP1A1/2 enzymes 
reconstituted with NADPH:CYP reductase to oxidize ellipticine depends on the 
CYP:reductase ratios in the reconstitution systems (figure 2). Furthermore,  
an increase in the concentration of CYP1A1 and 1A2 in incubations results  
in an increase in formation of ellipticine metabolites, predominantly  
in generation of 9-hydroxyellipticine and 7-hydroxyellipticine (figure 3).  
The results reflect the situation of ellipticine oxidation catalyzed by CYP1A1/2 
in human, rat and rabbit hepatic microsomes[20, 35].  
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Figure 2 The effect of NADPH:CYP reduktase on ellipticine oxidation by CYP1A1 (A) 
and CYP1A2 (B) in reconstituted system. The values are averages and standard 
deviations of triplicate incubations. 
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Figure 3 The effect of the different concentrations of cytochromes P450 1A1 (A) and 
1A2 (B) on ellipticine oxidation in reconstituted system. The values are averages and 
standard deviations of triplicate incubations. 
 
Ellipticine modulates its own pharmacological and genotoxic potencial  
by induction of CYP1A1/2 
Ellipticine was found to induce expression of CYP1A1 and CYP1A2 
enzyme proteins in livers (figure 4), lungs and kidneys (figure 5) of rats treated 
i.p. with this drug, thereby increasing their enzymatic activities. The ellipticine-
mediated CYP1A induction also increases the DNA adduct formation, which 
correlates with an increase in production of activation metabolites, responsible 
for the DNA adduct formation, as found in experiments following ellipticine 
oxidation by hepatic microsomes isolated from rats treated with 40 mg 
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ellipticine/kg (figure 6A). However, only an increase in oxidation of ellipticine 
to detoxication products, 9-hydroxy- and 7-hydroxyellipticine, was found in 
lung and kidney microsomes of rats treated with ellipticine (figure 6B,C).  
 
                                     
                                       
                      dose of  ellipticine                    dose of ellipticine 
                               (mg/kg of body weight)                 (mg/kg of body wieght) 
Figure 4 Induction of CYP1A1 (A, C) and 1A2 (B, D) in livers of male (A, B) and 
female rats (C, D) untreated and treated with 4, 40 and 80 mg/kg body weight 
ellipticine.Imunoblots of microsomal CYP1A1/2 are stained with antibody against rat 
CYP1A1.The values are averages and standard deviations of triplicate incubations, 
*p<0,05, **p<0,01, ***p<0,001 (Student´s t-test). 
 
 
 B  
 
Figure 5 Imunoblots of microsomal CYP1A1 and 1A2 from livers, lungs and kidneys 
of untreated and ellipticine-treated (40 mg/kg) male rats stained with antibody against 
rat CYP1A1. 
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Figure 6 Ellipticine metabolism in rat liver (A), lung (B) and kidney microsomes (C) 
of control animals and those treated with 40 mg/kg ellipticine. The values are 
averages and standard deviations of triplicate incubations, *p<0,05, **p<0,01, 
***p<0,001 (Student´s t-test).    
   
 
The rabbit apo-cytochrome b5 (cytochrome b5 without its heme cofactor) 
was prepared utilizing bovine myoglobin 
A biologically active apo-cytochrome b5 (without any damages in its 
protein function) was prepared using transfer of heme from purified rabbit 
cytochrome b5 to horse heart apo-myoglobin. This apo-cytochrome b5, after its 
reconstitution with hemin, reveals the properties identical to those of the native 
cytochrome b5. 
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Cytochrome b5 affects ellipticine oxidation by CYP1A1/2 and kinetics of 
this reaction  
Cytochrom b5 changed not only a simple enhancement of formation of all 
ellipticine metabolites in ellipticine oxidation by CYP1A1 and 1A2, but  
a different pattern and amounts of these metabolites were produced. Namely, 
cytochrome b5 stimulated generation of activation metabolites of ellipticine  
(12-hydroxy- and 13-hydroxyellipticine), while detoxication products of its 
oxidation were decreased (figure 7). Moreover, interaction between CYP1A1 
and cytochrome b5 changed the kinetics of ellipticine oxidation from hyperbolic 
to sigmoidal. On the contrary, no cooperativity was observed using the CYP1A2 
reconstitued system.  
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Figure 7 The effect of  cytochrome b5 on ellipticine oxidation by CYP1A1 (A) and  
1A2 (B). CYP1A1/2 and NADPH:CYP reduktase was used in molar ratio 1:1. The 
values are averages and standard deviations of triplicate incubations. 
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Cytochrome b5, but not its apo-form, changes the ellipticine oxidation by 
CYP1A1/2 
The heme cofactor of cytochrome b5 is essential for modulation of 
ellipticine oxidation by CYP1A1/2, which suggests that cytochrome b5 supports 
oxidation reactions due to an electron transfer among the enzymes of the CYP-
dependent enzymatic system (figure 8). No effect of apo-cytochrome b5 and/or 
other proteins with or without heme on ellipticine oxidation of CYP1A1/2 was 
found (figure 8). However, because not only a simple enhancement of formation 
of all ellipticine metabolites, but differences in patterns and amounts of these 
metabolites, were produced, the effect of cytochrome b5 on reactions catalyzed 
by CYP1A/2 probably results also from alteration of the protein conformation  
of both enzymes.   
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Figure 8 The effect of cytochrome b5 ,its apo-form and other compounds on ellipticine 
oxidation by CYP1A1 (A) and 1A2 (B). The values are averages and standard 
deviations of triplicate incubations. 
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Cytochrome b5 potentiates production of activation metabolites during 
ellipticine oxidation by CYP3A4  
Human and purified rabbit hepatic cytochrome b5 are also capable of stimulating 
oxidation of ellipticine by CYP3A4. Whereas the formation of detoxication 
product of ellipticine oxidation (9-hydroxyellipticine) is practically not changed 
by cytochrome b5, generation of 13-hydroxy- and 12-hydroxyellipticine,  
the metabolites responsible for formation of DNA adducts, is increased 
significantly by the cytochrome b5 protein (figure 9). These results correlate with 
an increase in the ellipticine-DNA adduct formation, mainly with generation of 
the major adduct 1, which is produced by 13-hydroxyellipticine. Interaction 
between CYP3A4 and cytochrome b5 causes an increase in the values of maximal 
velocities of ellipticine oxidation to all metabolites by CYP3A4, but does not 
change hyperbolic kinetics of ellipticine oxidation (as it was found in the 
CYP1A1/2 system). In addition, these findings correspond with binding  
of ellipticine to the active site of a CYP3A4 model, with its most populated 
binding mode. The results indicate that the presence of heme in cytochrome b5 
seems to be essential to stimulate CYP3A4-mediated oxidation of ellipticine 
(figure 9), but the allosteric modulation effect of this protein cannot be excluded. 
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Figure 9 The effect of cytochrome b5, its apo-form and other compounds on ellipticine 
oxidation by human CYP3A4. The values are averages and standard deviations  
of triplicate incubations. 
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The part of results of this PhD. thesis has already been published in scientific 
journals (see papers 1-4 of List of publications). Two other papers are  
in preparation (see papers 5 and 6 in List of publications). 
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